KR102166229B1 - 인지 및 운동 기능 증진제로서의 A2a 길항제 - Google Patents

인지 및 운동 기능 증진제로서의 A2a 길항제 Download PDF

Info

Publication number
KR102166229B1
KR102166229B1 KR1020197005483A KR20197005483A KR102166229B1 KR 102166229 B1 KR102166229 B1 KR 102166229B1 KR 1020197005483 A KR1020197005483 A KR 1020197005483A KR 20197005483 A KR20197005483 A KR 20197005483A KR 102166229 B1 KR102166229 B1 KR 102166229B1
Authority
KR
South Korea
Prior art keywords
levodopa
dopamine
effective amount
therapeutically effective
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020197005483A
Other languages
English (en)
Korean (ko)
Other versions
KR20190025734A (ko
Inventor
스테펜 아이. 반닥
케빈 제이. 블랙
메건 씨. 캠벨
Original Assignee
바이오티 세라피스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오티 세라피스, 인크. filed Critical 바이오티 세라피스, 인크.
Publication of KR20190025734A publication Critical patent/KR20190025734A/ko
Application granted granted Critical
Publication of KR102166229B1 publication Critical patent/KR102166229B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197005483A 2010-11-05 2011-11-04 인지 및 운동 기능 증진제로서의 A2a 길항제 Expired - Fee Related KR102166229B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2010/055681 2010-11-05
PCT/US2010/055681 WO2012060844A1 (en) 2010-11-05 2010-11-05 A2a antagonists as cognition and motor function enhancers
PCT/US2011/059466 WO2012061787A1 (en) 2010-11-05 2011-11-04 A2a antagonists as cognition and motor function enhancers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137014385A Division KR101955045B1 (ko) 2010-11-05 2011-11-04 인지 및 운동 기능 증진제로서의 A2a 길항제

Publications (2)

Publication Number Publication Date
KR20190025734A KR20190025734A (ko) 2019-03-11
KR102166229B1 true KR102166229B1 (ko) 2020-10-15

Family

ID=46024745

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197005483A Expired - Fee Related KR102166229B1 (ko) 2010-11-05 2011-11-04 인지 및 운동 기능 증진제로서의 A2a 길항제
KR1020137014385A Expired - Fee Related KR101955045B1 (ko) 2010-11-05 2011-11-04 인지 및 운동 기능 증진제로서의 A2a 길항제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137014385A Expired - Fee Related KR101955045B1 (ko) 2010-11-05 2011-11-04 인지 및 운동 기능 증진제로서의 A2a 길항제

Country Status (15)

Country Link
US (2) US20130317019A1 (enExample)
EP (1) EP2635256B1 (enExample)
JP (3) JP6315991B2 (enExample)
KR (2) KR102166229B1 (enExample)
CN (3) CN107281491A (enExample)
AU (3) AU2011323152A1 (enExample)
BR (1) BR112013011068A2 (enExample)
CA (1) CA2816834A1 (enExample)
EA (2) EA202091356A1 (enExample)
ES (1) ES2842968T3 (enExample)
HK (1) HK1245138A1 (enExample)
IL (2) IL225868B (enExample)
MX (2) MX382823B (enExample)
NZ (2) NZ609803A (enExample)
WO (2) WO2012060844A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6339758B2 (ja) * 2012-07-02 2018-06-06 国立研究開発法人国立長寿医療研究センター 軽度認知機能障害の有無の診断システム、認知機能検査用端末及び認知機能検査用プログラム
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي
AU2016278846B2 (en) 2015-06-19 2021-08-05 Biotie Therapies, Inc. Controlled-release tozadenant formulations
EP4501406A3 (en) * 2016-04-19 2025-03-26 IntraBio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
US11246871B2 (en) 2016-07-15 2022-02-15 Northwestern University Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
CN115397425A (zh) * 2019-12-02 2022-11-25 希诺皮亚生物科学公司 使用曲匹地尔治疗认知障碍

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261289A1 (en) * 2004-05-24 2005-11-24 Alexander Flohr 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
US20060178379A1 (en) * 2002-01-28 2006-08-10 Kyowa Hakko Kogyo Co., Ltd. Methods of treating patients suffering from movement disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
US8168785B2 (en) * 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178379A1 (en) * 2002-01-28 2006-08-10 Kyowa Hakko Kogyo Co., Ltd. Methods of treating patients suffering from movement disorders
US20050261289A1 (en) * 2004-05-24 2005-11-24 Alexander Flohr 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Also Published As

Publication number Publication date
IL225868B (en) 2019-05-30
HK1245138A1 (zh) 2018-08-24
MX382823B (es) 2025-03-13
KR20130143597A (ko) 2013-12-31
JP6315991B2 (ja) 2018-04-25
WO2012061787A1 (en) 2012-05-10
JP6611896B2 (ja) 2019-11-27
JP2019052163A (ja) 2019-04-04
EA202091356A1 (ru) 2020-12-30
AU2017201446A1 (en) 2017-03-23
WO2012060844A1 (en) 2012-05-10
CA2816834A1 (en) 2012-05-10
CN103429221A (zh) 2013-12-04
EP2635256A4 (en) 2014-05-21
US20130317019A1 (en) 2013-11-28
EA035900B1 (ru) 2020-08-28
JP2013541593A (ja) 2013-11-14
IL225868A0 (en) 2013-07-31
ES2842968T3 (es) 2021-07-15
BR112013011068A2 (pt) 2016-08-23
JP2017019829A (ja) 2017-01-26
NZ746118A (en) 2020-03-27
EP2635256B1 (en) 2020-10-21
NZ609803A (en) 2016-08-26
CN107281491A (zh) 2017-10-24
EA201390653A1 (ru) 2013-12-30
KR20190025734A (ko) 2019-03-11
AU2018286608B2 (en) 2020-07-30
CN109223799A (zh) 2019-01-18
EP2635256A1 (en) 2013-09-11
IL266321A (en) 2019-06-30
JP6444951B2 (ja) 2018-12-26
US20220125772A1 (en) 2022-04-28
AU2018286608A1 (en) 2019-01-24
KR101955045B1 (ko) 2019-03-06
MX2013005014A (es) 2014-01-31
AU2011323152A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
KR102166229B1 (ko) 인지 및 운동 기능 증진제로서의 A2a 길항제
Mao et al. Local infusion of an α-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys
JP2019524822A (ja) 神経変性疾患のための治療薬
KR20170086710A (ko) 피로의 치료 또는 예방 방법
KR20100014392A (ko) 섬유근통 치료용 드록시도파 및 약학 조성물
CN1293573A (zh) 迟发性运动障碍和其它运动疾病的治疗方法
US9271995B2 (en) Agent for ameliorating brain hypofunction
CN111542314B (zh) 神经退行性疾病的治疗剂
ES3004543T3 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP3721799A1 (en) Methods of treating brain disorders or identifying biomarkers related thereto
HK40003261A (en) A2a antagonists as cognition and motor function enhancers
HK1185811A (en) A2a antagonists as cognition and motor function enhancers
HK1185811B (en) A2a antagonists as cognition and motor function enhancers
CN111712239A (zh) 治疗不宁腿综合征的治疗剂
JP4834837B2 (ja) 精神神経疾患の治療薬
Zhang et al. Electro-acupuncture could be an effective pretreatment for cerebral ischemia
Rabin et al. Cholinergic components of frontal lobe function and dysfunction
Shinozaki et al. Stizolobic acid, a competitive antagonist for the quisqualate receptor at the crayfish neuromuscular junction

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

Not in force date: 20231009

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20231009

St.27 status event code: N-4-6-H10-H13-oth-PC1903